Ready to treat dry eye disease sooner?

Take the priorit eyes vevye® challenge

SEE HOW MANY OF YOUR NEW PATIENTS MAY BENEFIT FROM VEVYE

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- **Potential for Eye Injury and Contamination** – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
- **Use with Contact Lenses** – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information.

vevye®
(cyclosporine ophthalmic solution) 0.1%

prioriteyes care for patients like Alice*

Alice experienced 3 grades of improvement in tCFS after 1 month of VEVYE treatment*

OS at baseline



tCFS score: 3
SPEED score: 21/28

OS one month



tCFS score: 0
SPEED score: 10/28

*Based on a real-world patient. Name and image have been changed to protect privacy.

BCVA=best corrected visual acuity; NEI=National Eye Institute; SPEED=standardized patient evaluation of eye dryness; SPK=superficial punctate keratitis; VA=visual acuity.

ALICE | AGE 56
MARKETING PROFESSIONAL

DRY EYE JOURNEY

- Chronic open-angle glaucoma (COAG) managed with multiple preserved IOP-lowering therapies
- Seeking relief for dry eye symptoms

CHIEF COMPLAINTS

- Fluctuating visual acuity
- Burning, watering
- Symptoms exacerbated by prolonged screen time

CURRENT MEDICATIONS

- Bimatoprost 0.01%
- Timolol 0.5%
- Dorzolamide 2%

DIAGNOSTIC NOTES

- SPEED score: 21/28
- VA 20/30-2 OD and 20/25-2 OS BCVA
- Corneal staining score (tCFS): 3 (NEI scale 0-15)
- Persistent SPK

TREATMENT PLAN

- Rx: VEVYE® 0.1% BID OU
- Return to clinic: 1 month

prioriteyes care with VEVYE®

VEVYE combines a trusted molecule with a novel vehicle to deliver[1,2]:

RAPID AND SUSTAINED EFFICACY

- 56.8% of patients achieved ≥3 grades of total corneal fluorescein staining (tCFS) improvement vs vehicle as early as Day 15[3†]
- Statistically significant improvement in tCFS versus Restasis® at Days 29 and 85[4‡]
- Improvement from baseline in all measured symptoms (0-100 visual analog scale) over a 52-week period[5§]

PROVEN COMFORT FROM THE START

- 99.8% of patients experienced no or only mild instillation site pain[6]
- Only one patient discontinued treatment due to an ocular adverse event (n=202)[5§]

†Pooled, Phase 2b/3 and 3 randomized, double-masked clinical studies.
‡Phase 2, open-label, head-to-head study.
§Phase 3, open-label, 52-week extension study.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- **Potential for Eye Injury and Contamination** – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
- **Use with Contact Lenses** – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information.

vevye®
(cyclosporine ophthalmic solution) 0.1%

prioriteyes access for your patients

VEVYE® has partnered with specialty pharmacies to help your patients receive their VEVYE prescription at the lowest possible cost.*

COVERAGE IN 3 EASY STEPS

1 **ECP ePrescribes VEVYE directly from their EMR, or sends script by phone or fax**

alto

- 800-874-5881
- 415-484-7058
- 929 Broadway Denver, CO 80203

NPI: 1417411513

PHIL

- 855-977-5331
- mdsupport@phil.us
- my.phil.us

NPI: 1487163598

ScriptsRX

- 866-867-2703
- 877-991-1798
- 7515 Main Street, Suite 180, Houston, TX 77030

NPI: 1144730995

2 **Patient receives a text upon receipt confirming their prescription and assisting with coverage review, if required**

3 **ECP receives a status update when their patient's VEVYE is delivered; shipping is free**

VEVYE SAVINGS PROGRAM*

- Available through participating pharmacies
- Eligible patients may pay as little as $0
- 100% money-back guarantee
- Patient savings card is available at **GetVEVYE.com**

CASH-PAY OPTIONS*

$59 30-Day Supply

$165 90-Day Supply

ECP=eye care professional; EHR=electronic health record; NPI=national provider identifier.

***TERMS AND CONDITIONS**

Eligibility and restrictions apply. Coverage, reimbursement, and patient out-of-pocket costs vary by plan and are determined by the payer. Participation in support programs does not guarantee coverage or payment. For full program terms and conditions, please refer to the VEVYE® Access page at **VEVYE.com/hcp/access** (pharmacy fulfillment support) and the Savings Program page at **VEVYE.com/savings-program** (patient copay card).

For reimbursement and access education only. Not promotional.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information.

REFERENCES: 1. VEVYE® (cyclosporine ophthalmic solution) 0.1% [package insert]. Harrow IP, LLC. **2.** Sheppard JD, Wirta DL, McLaurin E, et al. Water-free 0.1% cyclosporine. A solution for treatment of dry eye disease: results of the randomized phase 2B/3 ESSENCE study. *Cornea.* 2021;40(10):1290-1297. doi:10.1097/ICO.0000000000002633 **3.** Akpek EK, Sheppard JD, Hamm A, Angstmann-Mehr S, Krösser S. Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract. *J Cataract Refract Surg.* 2024;50(6):644-650. doi:10.1097/j.jcrs.0000000000001423 **4.** Wirta DL, Torkildsen GL, Moreira HR, et al. A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. *Ophthalmology.* 2019;126(6):792-800. doi:10.1016/j.ophtha.2019.01.024 **5.** Wirta DL, Galor A, Aune CA, et al. Long-term safety and efficacy of a water-free cyclosporine 0.1% ophthalmic solution for treatment of dry eye. *Cornea.* 2024;44(6):692-700. doi:10.1097/ICO.0000000000003567 **6.** Data on file: ISS.

HARROW®

VYE-00378 05/26

vevye® (cyclosporine ophthalmic solution) 0.1%

Could your patients with persistent dry eye disease benefit from a change?

Take the prioriteyes vevye® challenge

SWITCH YOUR SYMPTOMATIC PATIENTS TO VEVYE AND SEE THE RESULTS

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- **Potential for Eye Injury and Contamination** – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
- **Use with Contact Lenses** – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information.

vevye®
(cyclosporine ophthalmic solution) 0.1%

prioriteyes care for patients like Bill*

Bill experienced 2 grades of improvement in tCFS after 1 month of VEVYE treatment*

OS at baseline



tCFS score: 2
SPEED score: 17/28

OS one month



tCFS score: 0
SPEED score: 8/28

*Based on a real-world patient. Name and image have been changed to protect privacy.

NEI=National Eye Institute; SPEED=standardized patient evaluation of eye dryness; VA=visual acuity.

BILL | AGE 61
ACCOUNTANT

DRY EYE JOURNEY

- Diagnosed with dry eye disease 5 years ago
- Presenting for comprehensive exam, with discomfort despite chronic dry eye medication

CHIEF COMPLAINTS

- Dryness and grittiness
- Symptoms worsen with outdoor activities

CURRENT MEDICATIONS

- Currently on Lifitegrast 5% BID OU (4 years)
- Previously failed on cyclosporine 0.05%

DIAGNOSTIC NOTES

- SPEED score: 17/28
- Fluctuating VA with acuities of 20/25 in each eye
- Corneal staining score (tCFS): 2 (NEI scale 0-15)

TREATMENT PLAN

- Rx: VEVYE® 0.1% BID OU
- Return to clinic: 1 month

prioriteyes care with VEVYE®

VEVYE combines a trusted molecule with a novel vehicle to deliver[1,2]:

RAPID AND SUSTAINED EFFICACY

- 56.8% of patients achieved ≥3 grades of total corneal fluorescein staining (tCFS) improvement vs vehicle as early as Day 15[3†]
- Statistically significant improvement in tCFS versus Restasis® at Days 29 and 85[4‡]
- Improvement from baseline in all measured symptoms (0-100 visual analog scale) over a 52-week period[5§]

PROVEN COMFORT FROM THE START

- 99.8% of patients experienced no or only mild instillation site pain[6]
- Only one patient discontinued treatment due to an ocular adverse event (n=202)[5§]

†Pooled, Phase 2b/3 and 3 randomized, double-masked clinical studies.
‡Phase 2, open-label, head-to-head study.
§Phase 3, open-label, 52-week extension study.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- **Potential for Eye Injury and Contamination** – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
- **Use with Contact Lenses** – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information.

vevye®
(cyclosporine ophthalmic solution) 0.1%

prioriteyes access for your patients

VEVYE® has partnered with specialty pharmacies to help your patients receive their VEVYE prescription at the lowest possible cost.*

COVERAGE IN 3 EASY STEPS

1 **ECP ePrescribes VEVYE directly from their EMR, or sends script by phone or fax**

alto

- 800-874-5881
- 415-484-7058
- 929 Broadway Denver, CO 80203

NPI: 1417411513

PHIL

- 855-977-5331
- mdsupport@phil.us
- my.phil.us

NPI: 1487163598

ScriptsRX

- 866-867-2703
- 877-991-1798
- 7515 Main Street, Suite 180, Houston, TX 77030

NPI: 1144730995

2 **Patient receives a text upon receipt confirming their prescription and assisting with coverage review, if required**

3 **ECP receives a status update when their patient's VEVYE is delivered; shipping is free**

VEVYE SAVINGS PROGRAM*

- Available through participating pharmacies
- Eligible patients may pay as little as $0
- 100% money-back guarantee
- Patient savings card is available at **GetVEVYE.com**

CASH-PAY OPTIONS*

$59 30-Day Supply

$165 90-Day Supply

ECP=eye care professional; EHR=electronic health record; NPI=national provider identifier.

***TERMS AND CONDITIONS**

Eligibility and restrictions apply. Coverage, reimbursement, and patient out-of-pocket costs vary by plan and are determined by the payer. Participation in support programs does not guarantee coverage or payment. For full program terms and conditions, please refer to the VEVYE® Access page at **VEVYE.com/hcp/access** (pharmacy fulfillment support) and the Savings Program page at **VEVYE.com/savings-program** (patient copay card).

For reimbursement and access education only. Not promotional.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information.

REFERENCES: 1. VEVYE® (cyclosporine ophthalmic solution) 0.1% [package insert]. Harrow IP, LLC. **2.** Sheppard JD, Wirta DL, McLaurin E, et al. Water-free 0.1% cyclosporine. A solution for treatment of dry eye disease: results of the randomized phase 2B/3 ESSENCE study. *Cornea.* 2021;40(10):1290-1297. doi:10.1097/ICO.0000000000002633 **3.** Akpek EK, Sheppard JD, Hamm A, Angstmann-Mehr S, Krösser S. Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract. *J Cataract Refract Surg.* 2024;50(6):644-650. doi:10.1097/j.jcrs.0000000000001423 **4.** Wirta DL, Torkildsen GL, Moreira HR, et al. A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. *Ophthalmology.* 2019;126(6):792-800. doi:10.1016/j.ophtha.2019.01.024 **5.** Wirta DL, Galor A, Aune CA, et al. Long-term safety and efficacy of a water-free cyclosporine 0.1% ophthalmic solution for treatment of dry eye. *Cornea.* 2024;44(6):692-700. doi:10.1097/ICO.0000000000003567 **6.** Data on file: ISS.

HARROW

VYE-00379 05/26

vevye® (cyclosporine ophthalmic solution) 0.1%